Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
2007
Challenges for Australia's Bio/Nanopharma Policies
publication
Evidence: moderate
Author Information
Author(s): Thomas A Faunce
Primary Institution: Australian National University
Hypothesis
How can Australia better support its bio/nanopharma sector through policy reforms?
Conclusion
The study highlights significant policy oversights that hinder the growth of Australia's bio/nanopharma industry.
Supporting Evidence
- Australia's pharmaceutical exports have increased, but imports remain high.
- Government policies have not adequately supported the generic pharmaceutical sector.
- Reference pricing is crucial for maintaining affordable medicine prices.
Takeaway
Australia needs to improve its policies to help local medicine makers and ensure people can afford their medicines.
Potential Biases
Potential bias from industry lobbying and insufficient consultation with generic manufacturers.
Limitations
The paper does not provide empirical data to support its claims.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website